



INDIAN PHARMACOPOEIA COMMISSION

National Coordination Centre- Pharmacovigilance Programme of India (PvPI)

MINISTRY OF HEALTH & FAMILY WELFARE, GOVERNMENT OF INDIA

SECTOR-23, RAJ NAGAR, GHAZIABAD- 201 002.

Tel No: 0120- 2783392, 2783400, 2783401,6582849 (Direct), Fax: 0120-2783311

e-mail: pvpi@ipcindia.net, ipclab@vsnl.net, Web: www.ipc.gov.in

File No. IPC/NCC-PvPI/DSA/2016-17/

April 2016

Drug Safety Alert

The preliminary analysis of SUSARs from the PvPI database reveals that the following drugs are associated with the risks as given below.

Table

S.No	Suspected Drugs	Indication	Adverse Reactions
1	Roflumilast	Reduce the risk of Chronic Obstructive Pulmonary Diseases exacerbations	Gynecomastia
2	Clozapine	Management of Schizophrenic patients	Neutropenia
3	Disulfiram	Alcohol-Abuse Deterrent	Erythroderma

Health care professionals, Patients/Consumers are advised to closely monitor the possibility of the above adverse events while prescribing/consuming above suspected drugs and report to the NCC-PvPI either by filling of Suspected Adverse Drug Reactions Reporting Form/ Medicines Side Effect Reporting Form for Consumer (<http://www.ipc.gov.in>) or by PvPI Helpline No. 1800-180-3024.

“Let us join hands with PvPI to ensure patients safety”

ADR Reporting Help line (Toll Free): 1800-180-3024